Monogram Biosciences Inc.  (MGRM) Trade Now »     Rate MGRM  -  Discuss MGRM  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

MGRM Analysis & Videos »


MGRM: Bull or Bear?

Monogram Must Manage Growth MGRM

We would like to see how Monogram manages its top- and bottom-line growth before we recommend the shares. Continue reading »

By  Zacks.com   (-12.96%  risk: moderate)  06/16/08

Comment

Medi-Cal Expands Coverage Of Baseline HIV Resistance Testing MGRM

61%

Monogram Biosciences, Inc. (Nasdaq: MGRM) announced today that Medi-Cal has expanded its coverage of HIV resistance testing to include treatment naive patients as well as patients failing therapy. While genotypic resistance testing has traditionally been covered for patients who fail anti-HIV treatment, the expanded coverage allows for baseline genotypic resistance testing for all HIV infected patients, including those who are newly diagnosed and who are treatment naïve. Medi-Cal is California's Medicaid program, which provides medical service coverage for low-income and disabled individual< />< />< /><>< /><><>... Continue reading »

By  Aircarp   (+12.00%  risk: aggressive)  06/18/07

Comment

Cutting loss MGRM

13%

I still like the company long term, but going out for now.  there's lack of catalyst in the ext yr or so.  The closest I think is the increased revenue from Trofile/CCR5 Maraviroc tie in.  In the long term, the cancer assays have the biggest potentials, but investors have to be really patient for it. Continue reading »

By  kuntilanak   (-8.35%  risk: aggressive)  05/10/07

Comment

Monogram licenses patent portfolio to Caliper on an exclusive basis and Q1 Results.. MGRM

61%

After the close this afternoon, Mongram BioSciences held a conference call to discuss the opportunity for Monogram's Trofile(TM) Assay in conjunction with Q1 results.  Dr. Andrew Zolopa, a leading HIV physician from Stanford provided a compelling overview of Mongram's Trofile test and the current opportunities with Pfizer's new HIV drug  Maravioc which recently received a unanimous recommendation from an FDA panel and pending approval. Some e... Continue reading »

By  Aircarp   (+12.00%  risk: aggressive)  05/03/07

Comment

mgrm 2007-2008-2009 MGRM

N/A

A Google search(by date) will tell you all you need to know about where MGRM fits into the world of personalized medicine. Well worth a look to anyone with an above average attention span and a better than average ability to realize the meaning of what he/she is reading.   Good Luck! Continue reading »

By  mikekato2002   (-97.82%  risk: aggressive)  04/29/07

Comment

Monogram Biosciences Expectations Too High! MGRM

61%

There were a lot of frustrated traders on the MGRM boards today blaming the market makers and shorts for manipulating the stock price and the company for not enough PR.  Longs (including myself) were hoping this drug would be used across the full spectrum (or at least half (500K)) of US HIV/AIDS patients.  Bottom line is that we can only expect 40K to use the drug in the US this year.  The good news is that this is still significant new revenue for the company.  $100 per test initially would not be out of line.  Many existing HIV/AIDS test are in the $50-70 range.  This< />< />< />< />< />< />... Continue reading »

By  Aircarp   (+12.00%  risk: aggressive)  04/25/07

Comment

Monogram Biosciences in Play MGRM

61%

An FDA advisory panel of outside experts is set to vote on Tuesday on whether to back approval for Pfizer's HIV drug candidate Maraviroc for patients already treated with other drugs. The FDA reviewers have already said their analyses of the drug's effectiveness were consistent with Pfizer's (PFE). The company's studies showed the HIV virus was suppressed in about 45 percent of patients who took the drug. Now it's down to the safety review tomorrow. Monogram has partnered with Pfizer with through it's diagnostic test, Trofile, that determines which patients are suited t... Continue reading »

By  Aircarp   (+12.00%  risk: aggressive)  04/23/07

Comment

Potential Upside with Trofile/Maraviroc MGRM

13%

Good news on Pfizer's Maraviroc at April 23 FDA review can be a potential upside for the stock.  MGRM's Trofile assay has been used to select patients in Maraviroc trial. Continue reading »

By  kuntilanak   (-8.35%  risk: aggressive)  04/20/07

Comment

People Bullish on MGRM

Wes Analyst 47% over 2 years ago	Aircarp Sr. Analyst 61% over 2 years ago	Baronnese Analyst N/A over 2 years ago
mikekato2002 Analyst N/A over 2 years ago	mabeaton Analyst  6 % over 2 years ago

People Bearish on MGRM

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.